Clinical Parameters to Predict Response to Interferon in Relapsing Multiple Sclerosis

Publisher： Karger

E-ISSN： 1423-0208|31|3|150-156

ISSN： 0251-5350

Source： Neuroepidemiology, Vol.31, Iss.3, 2008-08, pp. : 150-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is Interferon Effective and Safe for Relapsing-Remitting Multiple Sclerosis?

By  

Neuroepidemiology, Vol. 21, Iss. 6, 2002-11 ,pp. : 310-

Karger

Access to resources Recommend Favorite

Long-Term Adherence to Interferon β Therapy in Relapsing-Remitting Multiple Sclerosis

By  

European Neurology, Vol. 59, Iss. 3-4, 2007-11 ,pp. : 131-135

Karger

Access to resources Recommend Favorite

Seasonal Variations in Exacerbations and MRI Parameters in Relapsing- Remitting Multiple Sclerosis

By  

Neuroepidemiology, Vol. 23, Iss. 5, 2004-08 ,pp. : 217-223

Karger

Access to resources Recommend Favorite

Interferon-β1b in Multiple Sclerosis: Effect on Progression of Disability and Clinical Markers of Treatment Response

By  

European Neurology, Vol. 60, Iss. 6, 2008-09 ,pp. : 279-284

Karger

Access to resources Recommend Favorite

Patterns of Th1/Th2 Cytokines Predict Clinical Response in Multiple Sclerosis Patients Treated with Glatiramer Acetate

By  

European Neurology, Vol. 65, Iss. 3, 2011-03 ,pp. : 164-169

Karger

Access to resources Recommend Favorite